This Article Order Full text via Infotrieve Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tohgi, H. Articles by Watanabe, K. Search for Related Content PubMed PubMed Citation Articles by Tohgi, H. Articles by Watanabe, K.

Stroke, Vol 25, 2017-2021, Copyright © 1994 by American Heart Association

ARTICLES

Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin

H Tohgi, H Takahashi, M Kashiwaya and K Watanabe
Department of Neurology, Iwate Medical University, Morioka, Japan.

BACKGROUND AND PURPOSE: Elevated levels of plasma fibrinogen are a risk factor for cerebral infarction. Because fibrinogen plays a central role in platelet aggregation and binding of fibrinogen to platelets is inhibited by ticlopidine, we studied the effect of the plasma fibrinogen concentration on the antiaggregatory action of ticlopidine compared with that of aspirin. METHODS: We determined platelet aggregability before and after administration of ticlopidine (200 mg/d) or aspirin (81 mg/d) in 61 stroke patients and correlated the changes with the plasma fibrinogen concentration. RESULTS: In patients receiving ticlopidine, the platelet aggregability induced by 1, 5, and 10 mumol/L adenosine diphosphate significantly decreased compared with aggregability before medication (P < .05), and the reductions had significant negative correlations with the plasma fibrinogen concentration (P < .05). In patients receiving aspirin, the platelet aggregability induced by 2 micrograms/mL collagen and 5 and 10 mumol/L adenosine diphosphate decreased compared with aggregability before medication (P < .005), but the reductions had no significant correlation with the plasma fibrinogen concentration. CONCLUSIONS: The relative antiaggregatory effect of ticlopidine is significantly decreased with higher plasma fibrinogen concentrations. This may explain, at least in part, the individual variation in the response to ticlopidine.

This article has been cited by other articles:

				M. Di Napoli and F. Papa Inflammation, Hemostatic Markers, and Antithrombotic Agents in Relation to Long-Term Risk of New Cardiovascular Events in First-Ever Ischemic Stroke Patients Stroke, July 1, 2002; 33(7): 1763 - 1771. [Abstract] [Full Text] [PDF]

				T. E. WESSENDORF, A. F. THILMANN, Y.-M. WANG, A. SCHREIBER, N. KONIETZKO, and H. TESCHLER Fibrinogen Levels and Obstructive Sleep Apnea in Ischemic Stroke Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2039 - 2042. [Abstract] [Full Text]

				J. Ma, C. H. Hennekens, P. M. Ridker, and M. J. Stampfer A prospective study of fibrinogen and risk of myocardial infarction in the physicians' health study J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1347 - 1352. [Abstract] [Full Text] [PDF]